At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 99 enrolled
Drug / intervention
AL-78898A +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Controlled, Double-Masked, Randomized, Multicenter Study to Evaluate AL-78898A as a Treatment of Exudative AMD
In Brief
A Phase 2 clinical trial evaluating AL-78898A and Ranibizumab for Exudative Age-Related Macular Degeneration. Completed, enrolled 99 participants across 1 site.
Detailed Summary
The primary purpose of this study was to demonstrate a biological effect of AL-78898A, as measured by change (reduction) in central subfield (CSF) retinal thickness 4 weeks after a single intravitreal injection, as compared to LUCENTIS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2010
Enrollment StartJun 2011
Primary CompletionApr 2012
TodayJul 2026
First PostedJul 5, 2010
Enrollment StartJun 1, 2011
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 16.0 years ago
Interventions
AL-78898Adrug
Investigational treatment
Ranibizumabdrug
Anti-vascular endothelial growth factor (VEGF) treatment